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Scedosporium apiospermum is a mold that is increasingly being recognized as an oppor-
tunistic pathogen in immunocompromised patients, and treatment is complicated by
intrinsic resistance to several antifungal agents. In our hospital, two cases of S. apios-
permum infection occurring within 2 weeks were successfully treated with voriconazole.
Since both patients were infected with an uncommon pathogen, a search for a common
nosocomial source was performed. As environmental cultures yielded no S. apiospermum,
and random amplified polymorphic DNA (RAPD) fingerprinting showed that the
patients’ strains were genotypically unrelated, we considered a common nosocomial
source of S. apiospermum to be unlikely.
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I N T R O D U C T I O N
The genus Scedosporium contains two clinically
important species: Scedosporium apiospermum (the
asexual state of Pseudallescheria boydii), and Scedos-
porium prolificans. This saprophytic mold has a
worldwide distribution, with reservoirs in water
and soil. The most common presentations of sce-
dosporium infections are cutaneous mycetoma
and allergic bronchopneumonitis. Furthermore,
malignant otitis externa, brain abscess, arthritis
and invasive pulmonary infections have been des-
cribed, including pneumonia after near-drowning
and pulmonary colonization of cystic fibrosis
patients [1–6]. Immunocompromised patients are
at risk for often fatal disseminated scedosporiosis,
especially when they are neutropenic [7,8]. Com-
binations of surgical excision and cryosurgery are
used in the treatment of mycetoma of the skin and
underlying tissues, but are often mutilating, and
relapses occur [9]. Intrinsic resistance to flucona-
zole and amphotericin B complicates systemic
antifungal therapy of scedosporium infections.
Voriconazole is a promising broad-spectrum anti-
fungal azole drug that has proved efficacious in
treating invasive aspergillosis. In vitro data sug-
gest that S. apiospermum isolates can be suscep-
tible to voriconazole, itraconazole, and miconazole
[10–13]. Previously, voriconazole was used suc-
cessfully in the treatment of S. apiospermum infec-
tion [2,14,15].
Nosocomial outbreaks with S. prolificans have
been described, and S. apiospermum has been cul-
tured from potted plants in a hospital [16–18]. PCR
fingerprinting proved a useful tool in evaluating
an outbreak of S. prolificans infection in a hemato-
logic ward, where air samples yielding S. prolifi-
cans suggested airborne transmission [18]. We
used this technique to investigate the possible
relationship between two cases of S. apiospermum
infection occurring in our hospital within 2 weeks.
P A T I E N T S A N D M E T H O D S
Case reports
Case 1
A 59-year-old-kidney transplant recipient with
stable renal function (serum creatinine 111mmol/L)
received cyclosporin 75 mg twice daily (Neoral,
Novartis, Arnhem, The Netherlands), prednisone
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12.5 mg once daily, and azathioprine 150 mg once
daily. After a stay in Morocco, he was treated
parenterally for dehydration and diarrhea caused
by Campylobacter coli. Twenty-nine days after dis-
charge, he was readmitted with cellulitis at the
previous insertion site of an intravenous catheter
on the back of his left hand, without fever or chills.
Several purple nodules and slight desquamation
were observed, and MR imaging showed diffuse
subcutaneous infiltration of the hand and lower
arm, but no signs of osteomyelitis or arthritis. Skin
biopsy showed active granulomatous inflamma-
tion of the dermis, with hyphal fragments in the
deeper layers. Culture of the pus yielded S. apios-
permum, and blood cultures remained sterile.
Results of susceptibility testing according to the
M38P protocol of the National Committee for
Clinical Laboratory Standards (NCCLS) are shown
in Table 1 [12]. After 3 days of itraconazole, intra-
venous treatment with voriconazole was started
on the basis of compassionate use: 6 mg/kg every
12 h on the first day, and 4 mg/kg every 12 h
thereafter. Meanwhile, the lesion on the hand
was bandaged without the use of iodine or topical
antifungal agents. Before admission, the use of
cyclosporin was gradually being reduced in the
process of a planned conversion to azathioprine.
To avoid both the risk of disseminated scedospor-
iosis and the well known impairment of cyclos-
porin metabolism by azoles, cyclosporin was
stopped when itraconazole was started. Chest
radiography, ultrasound of the abdomen and total
body IgG scanning revealed no signs of dissemi-
nation. Because of the patient’s good clinical con-
dition and improving skin lesions, we switched to
oral voriconazole 200 mg twice daily, after 10 days
of parenteral therapy. Voriconazole serum levels
were above the MIC for the infecting strain
(>3.13 mg/L), as determined by bioassay [4,19].
After 6 weeks, voriconazole was stopped; the
patient had fully recovered without deterioration
of renal function.
Case 2
An 84-year-old male with a history of congestive
heart failure was using 10 mg prednisone once
daily for chronic obstructive pulmonary disease
(COPD), when he was admitted with a peripros-
thetic fracture of the proximal femur after he fell
in the street. A Girdlestone procedure was per-
formed, complicated postoperatively by abdom-
inal sepsis. A laparotomy was performed, and the
patient received piperacillin–tazobactam intrave-
nously for 7 days. During admission, chronic
inflammation with bullae had developed at the
site of an abrasion of the right elbow, from which S.
apiospermum was cultured. The results of suscept-
ibility testing are shown in Table 1. Intravenous
voriconazole was started, 6 mg/kg every 12 h on
the first day, and 4 mg/kg every 12 h thereafter.
The abrasion was treated conservatively. X-ray of
the elbow showed no signs of osteomyelitis.
Although there was a good initial response, the
patient died 10 days after voriconazole treatment
was started. Autopsy showed old and recent
myocardial infarction and bilateral bronchop-
neumonia. There was no evidence of pulmonary
or disseminated S. apiospermum infection: Grocott
and periodic-acid-schift staining of lung tissue
showed no fungal hyphae, and post-mortem cul-
tures of lungs, spleen and liver revealed no micro-
organisms, especially no fungi.
Environmental sampling and RAPD
fingerprinting
Since both patients were infected with an uncom-
mon pathogen within a 2-week period, we inves-
tigated the possibility of a common source of S.
apiospermum. As cutaneous infection with Scedos-
porium spp. is considered to be the result of direct
contact between skin and fungal spores, cultures
were taken from plasters, bandages, pads, and
skin disinfectants. However, S. apiospermum was
not cultured. The patients had never been in the
same ward, and there were no potted plants in
their surroundings. To investigate whether the
S. apiospermum strains of the patients were geno-
typically related, we performed random amplified
polymorphic DNA (RAPD) fingerprinting with
three primers (GC70, GC80, and M13), as
described by Ruiz-Diez et al. [20]. Fungal DNA
Table 1 Results of susceptibility testing of S. apiospermum
Antifungal agent
MIC (mg/L)
Case 1 Case 2
Amphotericin B 4 16
5-Flucytosine >64 >64
Fluconazole 16 32
Itraconazole 2 1
Voriconazole 0.5 0.5
Terbinafine >16 >16
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of both patients’ strains and three unrelated con-
trol strains was extracted using hexadecyltri-
methylammonium bromide (CTAB/NaCl 2% w/
v), RNase A (10 mg/mL), and chloroform–isoamyl
alcohol, followed by ethanol precipitation. PCR
products were visualized on agarose gel, and
the results of fingerprinting with the 10-mer pri-
mers GC70 and GC80 are shown in Figure 1. The
patients’ strains were genotypically unrelated, and
the control strains confirmed adequate discrimi-
native power.
D I S C U S S I O N
S. apiospermum infection of the skin and under-
lying tissues is a deep fungal infection, and the risk
of disseminated scedosporiosis in immunocom-
promised patients should not be underestimated.
As mentioned in this journal before [21], the opti-
mal treatment of S. apiospermum infections is not
known; treatment should include surgical debri-
dement when possible. In patients with S. apios-
permum infection of the hand and lower arm,
however, surgery may lead to amputation or loss
of hand function. In our opinion, systemic anti-
fungal drugs constitute the cornerstone of the
management of invasive fungal disease; suscept-
ibility testing can help in determining the drug
of choice. We found a low MIC (0.5 mg/L) for
voriconazole in both patients’ S. apiospermum
strains, and both patients responded to systemic
voriconazole therapy. Owing to this good clinical
response, extensive surgical debridement could be
avoided. Although we showed fairly good in vitro
susceptibility of S. apiospermum to miconazole in a
previous study (MIC90 1 mg/L) [12], we did not
use it for topical antifungal therapy, on the
assumption that the penetration of miconazole
into the deeper layers of the skin and underlying
tissues is unpredictable.
The use of an intravenous catheter at the site of
infection provided a probable site of entry for S.
apiospermum in the first patient. At the time of
removal of the peripheral catheter, there were
no signs of infection and the catheter was not
cultured. The second patient might have been
infected with S. apiospermum when he fell in the
street and fractured his femur. Negative environ-
mental sampling made bandage materials or dis-
infectants as sources of S. apiospermum infection
less likely. Although the primers GC70, GC80 and
M13 were originally described in RAPD finger-
printing of S. prolificans, GC70 was also suitable for
S. apiospermum fingerprinting [6,23]. However, the
fact that our patients’ S. apiospermum strains were
not genotypically related does not completely rule
out a common source in the hospital; genetic
polymorphism among molds may be very high,
as was shown for Aspergillus fumigatus [22]. How-
ever, only limited data are available on the genetic
variability in Scedosporium, although different gen-
otypes were found using RAPD and multilocus
enzyme electrophoresis [6,23].
C O N C L U S I O N
Voriconazole is a promising drug in the treat-
ment of S. apiospermum infections. Molecular
Figure 1 RAPD PCR Fingerprinting
S. Apiospermum with 2 primers.
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epidemiology is important in our understanding
of S. apiospermum as an emerging pathogen in
immunocompromised patients.
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